Metabolic syndrome among Chinese obese patients with epilepsy on sodium valproate

Introduction: We aim to define the iron deficiency prevalence and eventual differences between obese patients with and without metabolic syndrome.Material and Methods: Analysis of patients evaluated at multidisciplinary consultation of obesity in our institution between 2013 and 2015 (n = 260). Iron deficiency: ferritin levels < 15 ng/mL. Exclusion criteria: prior bariatric surgery; lack of ferritin or hemoglobin determinations.Results: We analyzed data from 215 patients (84.2% female) with a mean age of 42.0 ± 10.3 years. The median body mass index was 42.5 (40.0 - 46.8) kg/m2 and 52.1% had metabolic syndrome. Iron deficiency was present in 7.0%, with no differences between genders or between patients with or without metabolic syndrome. Hypertension was associated with lower prevalence of iron deficiency. Type 2 diabetes and hypertension patients had higher levels of ferritin. The multivariate analysis showed that metabolic syndrome and increasing body mass index were predictive of higher risk of iron deficiency while hypertension predicted lower odds of iron deficiency.Discussion: The prevalence of iron deficiency was similar in other published studies. Iron deficiency may be underdiagnosed if based only on ferritin concentrations. In our study, diabetes and hypertension appear to contribute to the increase in ferritin levels described in obesity.Conclusion: Ferritin may not be a reliable index for evaluating iron stores in obese patients, particularly when associated with comorbidities such as type 2 diabetes and hypertension. Further studies are needed to guide the diagnosis and iron supplementation in these patients.

Download Full-text

Effect of Weight Reduction on Metabolic Syndrome in Korean Obese Patients

Journal of Korean Medical Science ◽

10.3346/jkms.2004.19.2.202 ◽

2004 ◽

Vol 19 (2) ◽

pp. 202 ◽

Cited By ~ 17

Author(s):

Hye Soon Park ◽

Su Jung Sim ◽

Jung Yul Park

Keyword(s):

Metabolic Syndrome ◽

Weight Reduction ◽

Obese Patients

Download Full-text

Oxidative Stress and Metabolic Syndrome: Effects of Natural Dietary Antioxidants in Obese Patients with Insulin Resistance.

10.1210/endo-meetings.2010.part3.p9.p3-428 ◽

2010 ◽

pp. P3-428-P3-428

Author(s):

A Mancini ◽

GE Martorana ◽

V Di Donna ◽

E Leone ◽

S Raimondo ◽

...

Keyword(s):

Oxidative Stress ◽

Insulin Resistance ◽

Metabolic Syndrome ◽

Obese Patients ◽

Dietary Antioxidants

Download Full-text

Up-Regulation of mRNA Levels of 11β-Hydroxysteroid Dehydrogenase Type 1 in the Liver of Morbidly Obese Patients with Metabolic Syndrome

10.1210/endo-meetings.2011.part3.p8.p2-583 ◽

2011 ◽

pp. P2-583-P2-583

Author(s):

Esther Torrecilla-Garcia ◽

Gumersindo Fernandez-Vazquez ◽

David Vicent-Lopez ◽

Franco Sanchez-Franco ◽

Lucio Cabrerizo-Garcia ◽

...

Keyword(s):

Metabolic Syndrome ◽

Hydroxysteroid Dehydrogenase ◽

Morbidly Obese ◽

Mrna Levels ◽

Obese Patients

Download Full-text

Abdominal Obesity and Short-term Mortality in Critically Ill Patients with Sepsis: A Retrospective Cohort Study Based on the MIMIC-IV Database

10.21203/rs.3.rs-1040005/v1 ◽

2021 ◽

Author(s):

Zhou Lv ◽

Minglu Gu ◽

Miao Zhou ◽

Yanfei Mao ◽

Lai Jiang

Keyword(s):

Metabolic Syndrome ◽

Cohort Study ◽

Intensive Care ◽

Abdominal Obesity ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Obese Patients ◽

Short Term ◽

Icu Admission ◽

Short Term Mortality

Abstract Purpose: Multiple studies have demonstrated an obesity paradox such that obese septic patients have a lower mortality rate and a relatively favorable prognosis. However, less is known on the association between abdominal obesity and short-term mortality in patients with sepsis. We conducted this study to determine whether the obesity-related survival benefit remains among abdominal obese patients.Methods: A retrospective cohort study was conducted using data derived from the Medical Information Mart for Intensive Care IV database. Septic patients (≥18 years) with or without abdominal obesity of first intensive care units (ICU) admission in the database were enrolled. The primary outcome was mortality within 28 days of ICU admission and multivariable logistic regression analyses were employed to assess any association between abdominal obesity and the outcome variable.Results: A total of 21534 patients were enrolled finally, the crude 28-day mortality benefit after ICU admission was not observed in patients with abdominal obesity (15.8% vs. 15.3%, p=0.32). In the extended multivariable logistic models, the odds ratio (OR) of abdominal obesity was significantly inversed after incorporating metabolic variables into the logistic model (OR range 1.094-2.872, p = 0.02). The subgroup analysis showed interaction effects in impaired fasting blood glucose/diabetes and metabolic syndrome subgroups (P = 0.001 and <0.001, respectively). In the subgroups of blood pressure, high-density lipoprotein cholesterol, and triglyceride level, no interaction was detected in the association between abdominal obesity and mortality. After propensity score matching, 6523 pairs of patients were selected. The mortality significantly higher in the abdominal obesity group (17.0% vs. 14.8%, p = 0.015). Notably, the non-abdominal obese patients were weaned off vasopressors and mechanical ventilation more quickly than those in the abdominal obesity group (vasopressor‑free days on day 28 of 27.0 vs. 26.8, p < 0.001; ventilation-free days on day 28 of 26.7 vs. 25.6, p < 0.001).Conclusion: Abdominal obesity was associated with increased risk of adjusted sepsis-related mortality within 28 days after ICU admission and was partially mediated through metabolic syndrome components.

Download Full-text

The prevalence of metabolically healthy obesity according to the sample of the Moscow region

Obesity and metabolism ◽

10.14341/omet2017451-56 ◽

2017 ◽

Vol 14 (4) ◽

pp. 51-56 ◽

Cited By ~ 2

Author(s):

Elena V. Ostrovskaya ◽

Tatiana I. Romantsova ◽

Andrei N. Gerasimov ◽

Tamara E. Novoselova

Keyword(s):

Metabolic Syndrome ◽

Carbohydrate Metabolism ◽

Medical Records ◽

Density Lipoprotein ◽

Homa Index ◽

Obese Patients ◽

Hip Circumference ◽

Metabolically Healthy Obese ◽

Healthy Obese ◽

Metabolically Healthy

Introduction. Obesity is a major factor for cardiometabolic risk. However, there is a category of obese patients without disorders of lipid, carbohydrate metabolism and cardiovascular disease metabolically healthy obese (MHO). Aim. Our goal was to investigate the prevalence and characteristics of this phenotype compared to patients with metabolic syndrome (MS). Materials and methods. To evaluate the prevalence of the MHO phenotype we analyzed 389 medical records of females aged 1860 years with obesity. Three types of MHO criteria were used: 1) HOMA index (2.7); 2) IDF-criteria of metabolic syndrome, 2005; 3) the BioSHaRE-EU 2013 criteria (obese patients without any symptoms of MS). We conducted a comparative analysis of anthropometry, status of lipid and carbohydrate metabolism, the functional state of the liver. Results. The MHO prevalence was: 34.5% according to HOMA index, according to the definitions of MS 2005 38.6%, in BioSHaRE-EU 9.6%. In groups of MHO and MS dyslipidemia was observed in 27.3 and 49.5% (p0.05), hypertension in 25% and 71.6% (p0.05), steatogepatosis in 47.7% vs 51.3% (p0.05) of observations, respectively. Among comorbidities the gynecological pathology was most prevalent - 50.8 and 61.4% (p0.05), disorders of carbohydrate metabolism differed significantly in frequency- 6.82 and 39.1% of patients (p0.05). Patients with MHO had a shorter duration of the existence of obesity than MS (18.7 vs. 24 years) (p=0.0004) and less likely to have attempted to reduce weight 85.8% and 91.6%. Average BMI, waist circumference, hip circumference, fasting glucose, total cholesterol, insulin basal, basal C-peptide, HOMA index in groups of MHO and MS differed significantly (p0.05). Median ALT was 20 and 23.2 U/l, AST 20 and 23 U/l, triglycerides 1.1 and 1.8 mmol/l, high-density lipoprotein 1.4 and 1.1 mmol/l, respectively. Conclusions. The MHO prevalence was maximal according to the MS definitions from 2005, and minimal with BioSHaRE-EU criteria. The main analyzed indicators differed significantly in groups MHO and MS. Longer obesity existence in the MS group may suggest an instability of MHO phenotype over time.

Download Full-text